Guido Reber

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group
    Guido Reber
    Haemostasis Unit, Geneva University Hospital, Switzerland
    Thromb Haemost 88:66-73. 2002
  2. pmc Influence of antidepressants on hemostasis
    Demian Halperin
    Clinical Psychopharmacology Unit, Geneva University Hospitals, Geneva, Switzerland
    Dialogues Clin Neurosci 9:47-59. 2007
  3. ncbi A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism
    Philippe de Moerloose
    Angiology and Haemostasis Division, University Hospital of Geneva and Faculty of Medicine, Geneva Switzerland
    Thromb Haemost 100:505-12. 2008
  4. ncbi Technical aspects in laboratory testing for antiphospholipid antibodies: is standardization an impossible dream?
    Guido Reber
    Haemostasis Unit, Division of Angiology and Haemostasis, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland
    Semin Thromb Hemost 34:340-6. 2008
  5. pmc Variability between laboratories performing coagulation tests with identical platforms: a nationwide evaluation study
    Michael Nagler
    Division of Hematology and Central Hematology Laboratory, Luzerner Kantonsspital, Lucerne 16 CH 6000, Switzerland
    Thromb J 11:6. 2013
  6. ncbi In ECAT veritas?
    G Reber
    Genetics and Laboratory Medicine Department, Geneva University Hospital and Faculty of Medicine, University of Geneva, Switzerland
    Lupus 21:722-4. 2012
  7. ncbi Variability of anti-beta2 glycoprotein I antibodies measurement by commercial assays
    Guido Reber
    Division of Angiology and Haemostasis, Geneva University Hospital and Faculty of Medicine, Switzerland
    Thromb Haemost 94:665-72. 2005
  8. ncbi [Seventy years later: prothrombin time revisited]
    Guido Reber
    Unite d hémostase, Service d angiologie et hémostase, HUG, 1211 Geneve 14
    Rev Med Suisse 4:350-3. 2008
  9. ncbi Anti-beta2-glycoprotein I antibodies--when and how should they be measured?
    Guido Reber
    Division of Angiology and Haemostasis, University Hospital, Geneva, Switzerland
    Thromb Res 114:527-31. 2004
  10. ncbi A new rapid point-of-care D-dimer enzyme-linked immunosorbent assay (Stratus CS D-dimer) for the exclusion of venous thromboembolism
    Guido Reber
    Division of Angiology and Haemostasis, Geneva University Hospital, Switzerland
    Blood Coagul Fibrinolysis 15:435-8. 2004

Collaborators

Detail Information

Publications47

  1. ncbi Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group
    Guido Reber
    Haemostasis Unit, Geneva University Hospital, Switzerland
    Thromb Haemost 88:66-73. 2002
    ..Despite the large variability of anti-beta2-glycoprotein I measurements between centers, the agreement on results with high- and medium-positive samples was good...
  2. pmc Influence of antidepressants on hemostasis
    Demian Halperin
    Clinical Psychopharmacology Unit, Geneva University Hospitals, Geneva, Switzerland
    Dialogues Clin Neurosci 9:47-59. 2007
    ....
  3. ncbi A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism
    Philippe de Moerloose
    Angiology and Haemostasis Division, University Hospital of Geneva and Faculty of Medicine, Geneva Switzerland
    Thromb Haemost 100:505-12. 2008
    ..Our data indicate that the performances of Innovance D-Dimer, regardless of the analyzer, are similar to the reference methods, and that this assay can be used for the exclusion of venous thromboembolic disease...
  4. ncbi Technical aspects in laboratory testing for antiphospholipid antibodies: is standardization an impossible dream?
    Guido Reber
    Haemostasis Unit, Division of Angiology and Haemostasis, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland
    Semin Thromb Hemost 34:340-6. 2008
    ..Much more effort is needed to reduce the high interlaboratory variability in assay results even if absolute standardization cannot be feasibly achieved...
  5. pmc Variability between laboratories performing coagulation tests with identical platforms: a nationwide evaluation study
    Michael Nagler
    Division of Hematology and Central Hematology Laboratory, Luzerner Kantonsspital, Lucerne 16 CH 6000, Switzerland
    Thromb J 11:6. 2013
    ..In this study, we quantified the variance components when performing coagulation tests with identical analytical platforms in different laboratories and computed intraclass correlations coefficients (ICC) for each coagulation test...
  6. ncbi In ECAT veritas?
    G Reber
    Genetics and Laboratory Medicine Department, Geneva University Hospital and Faculty of Medicine, University of Geneva, Switzerland
    Lupus 21:722-4. 2012
    ..Therefore, we recommend the use of integrated assays, such as screen/confirm ratios, for the detection of weak LA samples...
  7. ncbi Variability of anti-beta2 glycoprotein I antibodies measurement by commercial assays
    Guido Reber
    Division of Angiology and Haemostasis, Geneva University Hospital and Faculty of Medicine, Switzerland
    Thromb Haemost 94:665-72. 2005
    ..In conclusion, additional efforts are however necessary, especially concerning the way to assess the cutoff point and the adoption of a reference calibrator, in order to improve standardization of the assays...
  8. ncbi [Seventy years later: prothrombin time revisited]
    Guido Reber
    Unite d hémostase, Service d angiologie et hémostase, HUG, 1211 Geneve 14
    Rev Med Suisse 4:350-3. 2008
    ..It is hoped that a comparable degree of standardization will be achieved for samples from patients with hepatic disease...
  9. ncbi Anti-beta2-glycoprotein I antibodies--when and how should they be measured?
    Guido Reber
    Division of Angiology and Haemostasis, University Hospital, Geneva, Switzerland
    Thromb Res 114:527-31. 2004
    ..We recommend abeta2GPI assays to be included in the panel of antiphospholipid screening tests. However, the standardisation of abeta2GPI assays has to be improved in order to ensure better comparability between the studies...
  10. ncbi A new rapid point-of-care D-dimer enzyme-linked immunosorbent assay (Stratus CS D-dimer) for the exclusion of venous thromboembolism
    Guido Reber
    Division of Angiology and Haemostasis, Geneva University Hospital, Switzerland
    Blood Coagul Fibrinolysis 15:435-8. 2004
    ..At 400 ng/ml, three results were false-negative, one with both devices and two with the Stratus D-dimer only. Stratus D-dimer appears to be suitable for the exclusion of venous thromboembolism in the emergency room setting...
  11. ncbi [Study of primary hemostasis in vitro with the Platelet Function Analyzer (PFA-100)]
    Guido Reber
    Division d Angiologie et Hémostase, Hopitaux Universitaires de Geneve
    Rev Med Suisse Romande 123:491-4. 2003
    ..This device appears an useful complement to aggregometry...
  12. ncbi Evaluation of advanced D-dimer assay for the exclusion of venous thromboembolism
    Guido Reber
    Division of Angiology and Haemostasis, Geneva University Hospital, Geneva 14, Switzerland
    Thromb Res 107:197-200. 2002
    ..5% (88.9, 98.8) and 47.8% (40.8, 54.9) at a cutt-off value of 1.1 microg/ml. This assay appears promising and should be validated in clinical practise to assess its place in the work-up schemes of thromboembolism...
  13. ncbi Performances of the fibrin monomer test for the exclusion of pulmonary embolism in symptomatic outpatients
    G Reber
    Division of Angiology and haemostasis and Medical Clinic 1, Geneva University Hospital, Switzerland
    Thromb Haemost 81:221-3. 1999
    ..In conclusion, this is the first study suggesting the interest of this Fibrin Monomer test to rule out PE; these results, however, need to be confirmed by other studies...
  14. ncbi Performances of a new, automated latex assay for the exclusion of venous thromboembolism
    G Reber
    Division of Angiology and Haemostasis, Geneva University Hospital, Switzerland
    Blood Coagul Fibrinolysis 12:217-20. 2001
    ..6-99.4). This new assay is fast and fully automated, and its performance is suitable to exclude venous thromboembolism. Management studies should be performed to assess its utility...
  15. ncbi Inability of serial fibrin monomer measurements to predict or exclude deep venous thrombosis in asymptomatic patients undergoing total knee arthroplasty
    G Reber
    Division of Angiology and Haemostasis, Geneva University Hospital, Switzerland
    Blood Coagul Fibrinolysis 11:305-8. 2000
    ..Therefore, despite differences between patients with or without DVT, serial FM determinations are of no value for predicting or ruling out DVT in individual patients undergoing total knee arthroplasty...
  16. ncbi Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction
    Nicolas Vuilleumier
    Service of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Geneva 14, Switzerland
    Eur Heart J 31:815-23. 2010
    ..Anti-apoA-1 IgG have been reported in MI without autoimmune disease, but their clinical significance remains undetermined...
  17. ncbi Inflammatory and prothrombotic states in obese children of European descent
    Sophie Stoppa-Vaucher
    Pediatric Endocrine and Diabetes Unit, Children s Hospital, University Hospitals and Faculty of Medicine, Geneva, Switzerland
    Obesity (Silver Spring) 20:1662-8. 2012
    ..Further investigation is necessary to determine if these cytokines, together with ETP, can reliably predict the development of diabetes and atherosclerosis...
  18. ncbi Immunization of LDL receptor-deficient mice with beta2-glycoprotein 1 or human serum albumin induces a more inflammatory phenotype in atherosclerotic plaques
    Sylvie Dunoyer-Geindre
    Service of Angiology and Hemostasis, University Hospital, Switzerland
    Thromb Haemost 97:129-38. 2007
    ..Statin treatment partially prevents these changes...
  19. ncbi Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome
    Nicolas Vuilleumier
    Division of Immunology and Allergy, Department of Internal Medicine, University Hospital, Geneva, Switzerland
    Clin Sci (Lond) 115:25-33. 2008
    ..These results emphasize the role of humoral autoimmunity as a mediator of inflammation and coronary atherogenesis...
  20. ncbi Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies
    Nathalie Satta
    Division of Angiology and Hemostasis, Faculty of Medicine, University Hospital of Geneva, 4 rue Gabrielle Perret Gentil, Geneva 14, Switzerland
    Blood 117:5523-31. 2011
    ..Our results demonstrate a role for TLR2 and CD14 in human endothelial cell and monocyte activation by aPLAs...
  21. ncbi The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies
    Nathalie Satta
    Division of Angiology and Hemostasis, University Hospital, Faculty of Medicine, Geneva, Switzerland
    Blood 109:1507-14. 2007
    ..Overexpression of human TLR2 in the TLR2-deficient EFs restituted the response to patient IgG. Our results imply that TLR2 plays a role in mouse fibroblast activation by APLAs...
  22. ncbi Agreement of a new whole-blood PT/INR test using capillary samples with plasma INR determinations
    Francoise Boehlen
    Haemostasis Unit, Department of Medicine, University Hospital, 1211 Geneva 14, Switzerland
    Thromb Res 115:131-4. 2005
    ....
  23. ncbi Discrepancy between capillary and venous International Normalised Ratio (INR) in a patient on vitamin-K antagonist: potentially serious clinical consequences
    Sophie Waldvogel Abramowski
    Haemostasis Unit, University Hospital of Geneva, 1211 Geneva 14, Switzerland
    Thromb Haemost 96:688-9. 2006
  24. ncbi Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease
    Nicolas Vuilleumier
    Division of Immunology and Allergy and Department of Internal Medicine, Geneva University Hospital, 24 Micheli du Crest, 1211 Geneva 14, Switzerland
    J Autoimmun 23:353-60. 2004
    ..76, P=0.0066) and anti-Apo A-1 IgG titre in ACS patients. The presence of anti-Apo A-1 autoantibodies in patients with ACS highlights an additional link between autoimmunity, inflammation and atherosclerosis...
  25. ncbi Fluvastatin increases the expression of adhesion molecules, monocyte chemoattractant protein-1 and tissue factor in HUVEC stimulated by patient IgG fractions containing antiphospholipid antibodies
    Sylvie Dunoyer-Geindre
    Unit of Haemostasis, University Hospital of Geneva, 24, Rue Micheli du Crest, 1211 Geneva 14, Switzerland, E mail
    Thromb Haemost 93:339-45. 2005
    ..Our results show that in cultured human EC, statins increase the extent of inflammatory activation induced by APLA. This effect appears to be mediated by an inhibitory effect of statins on one or more geranylgeranylated protein(s)...
  26. ncbi Antiphospholipid antibodies: do we still need to perform anticardiolipin ELISA assays?
    P de Moerloose
    Division of Angiology and Hemostasis, University Hospital, Geneva, Switzerland
    J Thromb Haemost 2:1071-3. 2004
  27. ncbi Thrombomodulin levels during normal pregnancy, at delivery and in the postpartum: comparison with tissue-type plasminogen activator and plasminogen activator inhibitor-1
    P de Moerloose
    Unite d hémostase, Hopital Cantonal Universitaire, Geneve, Switzerland
    Thromb Haemost 79:554-6. 1998
    ..Our data suggest that it would be more appropriate to take into account TM baseline values in a given woman to examine her TM increase during pregnancy...
  28. ncbi Superficial vein thrombosis of lower limbs: influence of factor V Leiden, factor II G20210A and overweight
    P de Moerloose
    Division d angiologie et d hémostase, Hôpital Universitaire Genève, Switzerland
    Thromb Haemost 80:239-41. 1998
    ..62, 95% CI 1.25-18.0) and with a BMI > or =28 kg/m2 (OR 3.74, 95% CI 1.05-15.1). In conclusion, both FV Leiden and overweight seem to predispose to SVT, a finding that should be confirmed in larger studies...
  29. ncbi Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism
    P de Moerloose
    Division of Angiology and Haemostasis, Unit, University Hospital of Geneva, Switzerland
    Br J Haematol 110:125-9. 2000
    ..No statistically significant differences were observed between patients and controls for the prothrombin G20210A mutation...
  30. ncbi Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome
    P de Moerloose
    Haemostasis Unit, Faculty of Medicine and University Hospital Geneva, Geneva, Switzerland
    J Thromb Haemost 8:1540-6. 2010
    ..Anticardiolipin (aCL) and anti-beta(2)glycoprotein I (abeta(2)GPI) antibodies are part of the criteria for antiphospholipid syndrome (APS). Therefore they are widely measured and about 30 commercial kits are available...
  31. ncbi Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation
    M Beghetti
    Cardiology Unit, Hopital des Enfants, Dept of Paediatrics, Geneva, Switzerland
    Eur Respir J 19:518-24. 2002
    ..Platelet aggregation inhibition may be one of the mechanisms which explains the beneficial effect of repeated inhalation of iloprost in pulmonary hypertension...
  32. ncbi Acquired factor XIII deficiency: a therapeutic challenge
    Francoise Boehlen
    Division of Angiology and Haemostasis, University Hospitals of Geneva and Faculty of Medicine of Geneva, 1211 Geneva 14, Switzerland
    Thromb Haemost 109:479-87. 2013
    ..After a review of the management of acquired FXIII deficiency patients and based on the management of acquired haemophilia we discuss a possible strategy for such difficult cases...
  33. ncbi A novel frameshift mutation in FGA (c.1846 del A) leading to congenital afibrinogenemia in a consanguineous Syrian family
    Emmanuel Levrat
    Division of Angiology and Haemostasis, University Hospital, Geneva, Switzerland
    Blood Coagul Fibrinolysis 22:148-50. 2011
    ....
  34. ncbi HPA-genotyping and antiplatelet antibodies in female blood donors
    Francoise Boehlen
    Hemostasis Unit, Division of Angiology and Hemostasis Department of Medicine, University Hospital, Geneva, Switzerland
    Hematol J 4:441-4. 2003
    ..Although none of the recipients developed passive alloimmune thrombocytopenia, this aspect of blood transfusion safety should be addressed by a large prospective trial...
  35. ncbi Evaluation of unfractionated heparin and recombinant hirudin on survival in a sustained ovine endotoxin shock model
    Eduardo R C Schiffer
    Division of Anesthesiological Investigations, University Medical Center, Geneva, Switzerland
    Crit Care Med 30:2689-99. 2002
    ..To compare and evaluate the potential benefit of two different anticoagulation regimens during endotoxemia in an ovine model...
  36. ncbi Point of care management of heparin administration after heart surgery: A randomized, controlled trial
    Paolo G Merlani
    Service of Surgical Intensive Care, Department of Anesthesiology, Pharmacology and Surgical Intensive Care, University of Geneva Hospitals and Faculty of Medicine University of Geneva, Geneva, Switzerland
    Intensive Care Med 32:1357-64. 2006
    ..We sought to shorten the time to obtain coagulation results and the desired coagulation state and to reduce blood loss and transfusions using point of care (POC) aPTT determination...
  37. ncbi Aspirin inhibits endothelial cell activation induced by antiphospholipid antibodies
    S Dunoyer-Geindre
    Division of Angiology and Hemostasis, University Hospital, Geneva, Switzerland
    J Thromb Haemost 2:1176-81. 2004
    ..Currently, treatment of patients with the antiphospholipid syndrome includes aspirin, particularly for women with recurrent fetal loss...
  38. ncbi Haemostatic properties of human pulmonary and cerebral microvascular endothelial cells
    G E Grau
    Department of Anaesthesiology, University Hospital, Geneva, Switzerland
    Thromb Haemost 77:585-90. 1997
    ..It is concluded that MVEC display different haemostatic features depending on the tissue they come from and that lung MVEC from ARDS patients present a procoagulant profile when compared with those from controls...
  39. ncbi Localization of beta2-glycoprotein 1 in late endosomes of human endothelial cells
    S Dunoyer-Geindre
    Division of Angiology and Haemostasis, University Hospital of Geneva, Switzerland
    Thromb Haemost 85:903-7. 2001
    ..The accumulation of anti-beta2GP1 antibodies in late endosomes of endothelial cells and the resulting modification of intracellular protein trafficking may contribute to the pathogenic effects of these antibodies...
  40. ncbi NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies
    Sylvie Dunoyer-Geindre
    Division of Angiology and Haemostasis, University Hospital of Geneva, Geneva, Switzerland
    Thromb Haemost 88:851-7. 2002
    ..Taken together our results imply that NFkappaB is an essential intermediate in the activation of EC by anti-beta(2)GP1 antibodies...
  41. ncbi Assessing aspirin responsiveness using the Verify Now Aspirin assay
    P Fontana
    Division of Angiology and Hemostasis, Department of Internal Medicine, Faculty of Medicine and University Hospitals of Geneva, Geneva, Switzerland
    Thromb Res 121:581-2. 2008
  42. ncbi D-dimer levels during delivery and the postpartum
    M Epiney
    Department of Obstetrics and Gynecology, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland
    J Thromb Haemost 3:268-71. 2005
    ..Only a few studies have reported measurements of DD levels in the postpartum...
  43. ncbi Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers
    P Fontana
    Department of Internal Medicine, Faculty of Medicine, Division of Angiology and Hemostasis, University Hospitals of Geneva, Geneva, Switzerland
    J Thromb Haemost 4:813-9. 2006
    ..Some data suggest that biological 'resistance' to aspirin or clopidogrel may influence clinical outcome...
  44. ncbi Anticoagulation by ancrod for carbon dioxide removal by extracorporeal membrane lung in the dog
    M E Sinclair
    Department of Surgery, Geneva University Hospital, Switzerland
    J Thorac Cardiovasc Surg 97:275-81. 1989
    ..We conclude that, despite the drop in coagulation factors and in alpha 2-antiplasmin activity during bypass, ancrod can be considered as a valuable alternative anticoagulant for extracorporeal carbon dioxide removal...
  45. ncbi Not all statins interfere with clopidogrel during antiplatelet therapy
    F Mach
    University Hospital, Geneva, Switzerland
    Eur J Clin Invest 35:476-81. 2005
    ..The objective of the present study was to define which statin might interfere with the antiaggregation property of clopidogrel...
  46. ncbi Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies
    Angela Tincani
    Rheumatology and Clinical Immunology, Ospedale Civile di Brescia, Piazza Spedali Civili 1, 25125 Brescia, Italy
    Thromb Res 114:553-8. 2004
    ..We suggest to adopt these "requirements" particularly in clinical studies, in order to compare more easily the literature data...
  47. ncbi An analysis of experimental conditions influencing the anti-beta2-glycoprotein I ELISA assay results
    Anna Cavazzana
    Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Padua, Padua, Italy
    Ann N Y Acad Sci 1109:484-92. 2007
    ..As variations in abeta(2)GPI ELISA conditions determine significant differences in the results, selecting the appropriate test variables is an important step toward abeta(2)GPI assay standardization...